Dermot Mark Durcan
Known title: DirectorCIK: 0001202358
Dermot Mark Durcan's purchase track record
Dermot Mark Durcan has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/18/2026 | COR | $1.10M | +13.8% | pending | — |
| 5/28/2026 | COR | $1.07M | +20.0% | pending | — |
| 5/24/2024 | COR | $109K | +8.8% | +12.4% | +12.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| COR | ▲ Buy | Open Market | 4,000 | $1.1M | 6/18/2026 | View on chart |
| COR | ▲ Buy | Open Market | 4,000 | $1.1M | 5/28/2026 | View on chart |
| COR | ▲ Buy | Grant | 905 | $325K | 3/5/2026 | View on chart |
| COR | ▲ Buy | Grant | 986 | — | 3/6/2025 | View on chart |
| COR | ▲ Buy | Open Market | 500 | $109K | 5/24/2024 | View on chart |
| COR | ▲ Buy | Grant | 1,053 | — | 3/12/2024 | View on chart |
| COR | ▲ Buy | Grant | 1,593 | — | 3/11/2024 | View on chart |
| COR | ▲ Buy | Grant | 1,667 | — | 3/9/2023 | View on chart |
| COR | ▲ Buy | Option Exercise | 2,012 | — | 3/5/2023 | View on chart |
| COR | ▲ Buy | Option Exercise | 2,101 | — | 2/28/2022 | View on chart |
| COR | ▲ Buy | Grant | 265 | $33K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects
Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.